SecBot SecBot

ACIU

AC Immune SA
Nasdaq· Pharmaceutical Preparations· Inc. V8· CIK 0001651625 Biotech & Drug Discovery
$2.42 −0.08 (−3.20%)
Oct 23 4:00 PM ET · prev $2.50
Market cap
$254.4M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
🔒 Subscribers only
1 year
−25.5%
from $3.25 · Oct 24
30 days
−9.0%
from $2.66
52-week range
$2.12–3.84
−37% from high · low Jun 10
Avg volume 20D
181.0K
shares / day
Short interest
3.52M
≈3.5% of shares · +1.4%
Days to cover
18.7
at average volume
Insider net
-$27.9K
1 buyer · 1 seller · 12 mo
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 4 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 6/10 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH AC Immune reported positive week-100 safety and immunogenicity data from Part 1 of the VacSYn Phase 2 trial…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider bought $31.4K at an average $3.14. 1 insider sold $59.4K. Price is 23% below their cost.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +1.4% to 3.52M shares. 18.7 days to cover, ≈3.5% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy5Buy4Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 23, 2026BTIG
REITERATE
REITERATEBuy
Aug 20, 2026BTIG
REITERATE
REITERATEBuy
Aug 5, 2026BTIG
REITERATE
REITERATEBuy
May 4, 2026BTIG
REITERATE
REITERATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Aug 20, 2026
FDA
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting…
Aug 11, 2026
FDA
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
AC Immune receives Fast Track designation and IND clearance from the FDA for anti-alpha-synuclein active immunotherapy to treat early Parkinson's…
Aug 5, 2026
Earnings
AC Immune First Half 2026 Financial and Corporate Update
AC Immune First Half 2026 Financial and Corporate Update
Aug 3, 2026
Earnings date
ACIU Q2 2026 Earnings Scheduled — 2026-08-03
Jul 30, 2026
Earnings date
ACIU Q2 2026 Earnings Scheduled — 2026-07-30

Insider ledger

Form 4
$31.4K
bought · 1 insider
$59.4K
sold · 1 insider
−23.0%
vs their $3.14 cost
DateInsiderTypeValue
Jun 11, 2026
June Carl Howard
Director
AWARD16,568 sh
Jun 11, 2026
June Carl Howard
Director
AWARD38,889 sh
Jun 11, 2026
Buetler Monika
Director
AWARD17,751 sh
Jun 11, 2026
Buetler Monika
Director
AWARD41,667 sh
Jun 11, 2026
Zuegel Martin
Interim CEO
AWARD33,136 sh
Jun 11, 2026
Zuegel Martin
Interim CEO
AWARD77,778 sh
Jun 11, 2026
AGUIAR-LUCANDER RENEE
Director
AWARD16,568 sh
Jun 11, 2026
AGUIAR-LUCANDER RENEE
Director
AWARD38,889 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
3,524,624
shares short
+1.4%
vs prior settlement
18.7
days to cover
≈3.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 9, 2026 SEC
Thomas Graney filed an amended Form 3 (3/A) to add a Power of Attorney as Exhibit 24. The filing reports his…
3/A — Impact 2/10
Oct 9, 2026 SEC
Thomas Graney filed a Form 3 initial statement of beneficial ownership with the SEC, reporting 12,959 common shares…
3 — Impact 2/10
Oct 2, 2026 SEC
AC Immune SA held an Extraordinary General Meeting on October 2, 2026, where shareholders approved the election of Tom…
6-K — Impact 2/10
Aug 20, 2026 Press
AC Immune announced positive preliminary Phase 1 data for its wholly-owned NLRP3 inhibitor ACI-19764, showing safety…
Impact 5/10
Aug 20, 2026 FDA
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating
Aug 11, 2026 Press
AC Immune received FDA Fast Track designation and IND clearance for its wholly owned anti-alpha-synuclein active…
Impact 7/10
Jun 11, 2026 Insider
June Carl Howard was granted 16,568 shares
Director
Jun 11, 2026 Insider
June Carl Howard was granted 38,889 shares
Director

SecBot reports

15 filings · 7 press releases · 4 bullish · 0 bearish · 1 mixed · 10 neutral
All ACIU filing & press-release reports (22)